Access detailed search options for content from the Clinical Journal of Oncology Nursing & Oncology Nursing Forum below.
Oncology advanced practice providers should have comprehensive knowledge and competency in the area of survivorship care. This module explores the considerations and principles of comprehensive survival care of the patient with cancer.
This module explores the considerations and principles of caring for older adults with cancer. Learn assessment tools, care modifications, pharmacologic principles, and treatment considerations specific to older adults with cancer, which will prepare advanced practice providers for the anticipated surge in survivors in this age group.
This comprehensive course will enhance your understanding of hematopoietic stem cell transplant (HSCT) and provide concepts to apply to your care of HSCT patients.
This module explores the considerations and principles of comprehensive survivorship care of patients with cancer. Learn considerations of each treatment modality, psychosocial and spiritual impacts of treatment, best practice, and the essential influence of the advanced practice provider in care of the cancer survivor.
This introductory course provides a foundation for providing care to patients experiencing a cancer diagnosis, treatment complications, or trouble coping. You’ll cover a range of basic topics, from cancer biology, treatments, symptom management, and patient and family care.
Learn how to care for patients with cancer by starting at the beginning. The Foundations of Oncology Nursing Practice Bundle consists of three individual courses that will guide you through a progression of topics, starting with an explanation of what cancer is and how it forms, to how it’s treated, and ends with how to safely administer chemotherapy and immunotherapy.
When OpdualagTM (nivolumab and relatlimab-rmbw), a fixed-dose combination therapy that consists of two distinct monoclonal antibodies, received FDA approval on March 18, 2022, for the treatment of unresectable or metastatic melanoma for adult and pediatric patients 12 years of age or older, it became the first approved combination therapy that includes two distinct immunotherapy agents in a single infusion. Relatlimab-rmbw is also the first approved lymphocyte activation gene-3 (LAG-3)–blocking antibody.
Erdafitinib (Balversa™) is the first targeted therapy that the U.S. Food and Drug Administration (FDA) approved for treatment of metastatic bladder cancer.